{"id":229250,"date":"2026-01-18T09:07:14","date_gmt":"2026-01-18T15:07:14","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/01\/nivolumab-and-ipilimumab-combination-treatment-in-advanced-dmmr-msi-h-noncolorectal-cancers"},"modified":"2026-01-18T09:07:14","modified_gmt":"2026-01-18T15:07:14","slug":"nivolumab-and-ipilimumab-combination-treatment-in-advanced-dmmr-msi-h-noncolorectal-cancers","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/01\/nivolumab-and-ipilimumab-combination-treatment-in-advanced-dmmr-msi-h-noncolorectal-cancers","title":{"rendered":"Nivolumab and Ipilimumab Combination Treatment in Advanced dMMR\/MSI-H Noncolorectal Cancers"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/nivolumab-and-ipilimumab-combination-treatment-in-advanced-dmmr-msi-h-noncolorectal-cancers2.jpg\"><\/a><\/p>\n<p>In a nonrandomized phase 2 trial of adults with advanced dMMR\/MSI-H noncolorectal cancers, combined nivolumab\/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%.<\/p>\n<hr>\n<p>Main Outcomes and Measures The co-primary end points were objective response rate (ORR) and 6-month progression-free survival (6-PFS) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with the secondary end points being median overall survival (mOS), progression-free survival (PFS), and treatment-related toxic effects.<\/p>\n<p>Results Overall, 52 participants were included. The median (range) age of participants was 62 (29\u221284) years; 41 (79%) were female individuals and 11 (21%) were male individuals. Overall, 52 patients representing 17 tumor types were enrolled, with the most common tumor type being endometrial cancer (26 [50%]). Twenty-seven patients (52%) were pretreated for metastatic disease. ORR was 63% (95% CI, 50% to 75%) with the median duration of response not being reached and 79% of responses being ongoing. The median PFS and OS have not been reached and the 6-month PFS was 71% (95% CI, 57%-81%). Overall, 12 patients (23%) experienced a grade 3\/4 immune-related adverse event.<\/p>\n<p><strong>Conclusions and Relevance<\/strong> This nonrandomized clinical trial found that combined anti\u2013PD-1\/CTLA-4 blockade was associated with a high rate of durable responses in dMMR\/MSI-H noncolorectal cancers, comparing favorably to published trials using anti\u2013PD-1\/programmed cell death ligand 1 monotherapy. Anti\u2013PD-1\/CTLA-4 blockade using nivolumab and ipilimumab may represent an alternative treatment option to monotherapy in this patient population.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a nonrandomized phase 2 trial of adults with advanced dMMR\/MSI-H noncolorectal cancers, combined nivolumab\/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%. Main Outcomes and Measures The co-primary end points were objective response rate (ORR) and 6-month progression-free survival (6-PFS) as assessed by Response Evaluation Criteria in Solid [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-229250","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=229250"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229250\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=229250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=229250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=229250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}